AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-188632462/polyphor-enter-into-exclusive.html" title="Facts and information about Polyphor to enter into an exclusive agreement with Allergan for the development of Protein Epitope Mimetics (PEM) inhibitors for ophthalmology.">Polyphor to enter into an exclusive agreement with Allergan for the development of Protein Epitope Mimetics (PEM) inhibitors for ophthalmology.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Polyphor to enter into an exclusive agreement with Allergan for the development of Protein Epitope Mimetics (PEM) inhibitors for ophthalmology.
Polyphor Ltd has entered into an exclusive worldwide discovery and licence agreement with Allergan Inc, under which Allergan obtains the rights to develop Protein Epitope Mimetics (PEM) cytokine inhibitors for the treatment of conditions and diseases of the eye. Under the agreement, Allergan and Polyphor will conduct a research programme designed to identify compounds that are optimally suited for local delivery to the eye in combination with …
Related articles from newspapers, magazines, journals, and more
